Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRISPR Therapeutics AG

52.17
+0.50000.97%
Post-market: 52.170.00000.00%16:58 EDT
Volume:1.84M
Turnover:95.50M
Market Cap:4.51B
PE:-11.55
High:53.08
Open:52.36
Low:51.15
Close:51.67
Loading ...

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?

Zacks
·
04 Jun

Promising Growth and Diversification Drive Buy Rating for Crispr Therapeutics AG

TIPRANKS
·
04 Jun

The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip

Motley Fool
·
02 Jun

New Hope for Strokes And Heart Attacks -- Barron's

Dow Jones
·
31 May

CRISPR Therapeutics AG's Chief Medical Officer Naimish Patel Reports Disposal of Common Shares

Reuters
·
31 May

Cathie Wood’s ARK Investment buys 294K shares of Crispr Therapeutics today

TIPRANKS
·
30 May

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

Dow Jones
·
29 May

Strokes and Heart Attacks Kill. New Drugs Are Coming to Prevent Them. -- Barrons.com

Dow Jones
·
23 May

Mizuho Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)

TIPRANKS
·
22 May

Crispr Therapeutics Price Target Maintained With a $86.00/Share by JMP Securities

Dow Jones
·
21 May

Mizuho Cuts Price Target on CRISPR Therapeutics to $85 From $99, Keeps Outperform Rating

MT Newswires Live
·
21 May

Crispr Therapeutics call volume above normal and directionally bullish

TIPRANKS
·
21 May

Strategic Growth and De-risking: Gil Blum’s Buy Rating on Crispr Therapeutics AG

TIPRANKS
·
20 May

Truist Financial Remains a Buy on Crispr Therapeutics AG (CRSP)

TIPRANKS
·
20 May

Buy Rating for CRISPR Therapeutics: Strategic Collaboration with Sirius Therapeutics to Enhance Pipeline and Capture Anticoagulant Market Share

TIPRANKS
·
20 May

5 Monster Stocks to Hold for the Next 10 Years

Motley Fool
·
20 May

CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy?

Motley Fool
·
20 May

CRISPR, Sirius Collaborate on RNA Therapy Targeting Blood Clot Disorders

MT Newswires Live
·
20 May

Crispr Therapeutics AG Partners with Sirius on siRNA Tech

TIPRANKS
·
20 May

Crispr Therapeutics And Sirius Therapeutics Announce Multi-Target Collaboration To Develop Novel Sirna Therapies

Reuters
·
20 May